Trial · NCT03278028

A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts

NCT03278028, Phase 2, Completed, Aclaris Therapeutics, Inc.; results first posted 2019-03-29

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts. Trials, record NCT03278028. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03278028

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts
NCT number: NCT03278028
Status: Completed
Phases: Phase 2
Enrollment: 159 participants, actual
Lead sponsor: Aclaris Therapeutics, Inc.
Conditions: Common Wart
Interventions: A-101 Topical Solution, A-101 Vehicle Solution
First posted: 2017-09-11
Last updated: 2019-04-09
Results first posted: 2019-03-29

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Physician's Wart Assessment	Day 57	Physician's Wart Assessment Grade Descriptor 0 Clear: No visible wart. No further treatment is indicated. 1. Near Clear: A visible wart that is less than 3 mm in maximal diameter (or length) 2. A visible wart ≥ 3 mm and \< 6 mm in maximal diameter (or length) 3. A visible wart ≥ 6 mm in maximal diameter (or length)

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Physician's Wart Assessment	Day 57	Per-Protocol (PP)	score on a scale	MEAN

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Physician's Wart Assessment	Active		1.52	Standard Deviation 1.06	score on a scale
Physician's Wart Assessment	Vehicle		2.23	Standard Deviation 0.66	score on a scale

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Active	81
Overall Study	STARTED	Vehicle	78
Overall Study	COMPLETED	Active	77
Overall Study	COMPLETED	Vehicle	76
Overall Study	NOT COMPLETED	Active	4
Overall Study	NOT COMPLETED	Vehicle	2

Source ClinicalTrials.gov

Adverse events90

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Tympanic Membrane Perforation	Ear and labyrinth disorders	Active	1	81	1
other	Tympanic Membrane Perforation	Ear and labyrinth disorders	Vehicle	0	78	0
other	Constipation	Gastrointestinal disorders	Active	0	81	0
other	Constipation	Gastrointestinal disorders	Vehicle	2	78	2
other	Diarrhoea	Gastrointestinal disorders	Active	1	81	1
other	Diarrhoea	Gastrointestinal disorders	Vehicle	0	78	0
other	Irritable Bowel Syndrome	Gastrointestinal disorders	Active	1	81	1
other	Irritable Bowel Syndrome	Gastrointestinal disorders	Vehicle	0	78	0
other	Vomiting	Gastrointestinal disorders	Active	1	81	1
other	Vomiting	Gastrointestinal disorders	Vehicle	0	78	0

1 to 10 of 90Source ClinicalTrials.gov

See all 90 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Active	0	81
Total, all-cause mortality	Vehicle	0	78
Total, other adverse events	Active	28	81
Total, other adverse events	Vehicle	19	78
Total, serious adverse events	Active	0	81
Total, serious adverse events	Vehicle	0	78

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Active vs Vehicle: deaths from any cause	Trial comparisons
Active vs Vehicle: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03278028

GET https://conductscience.org/api/trials/v1/NCT03278028/events?page=2

API reference For AI assistants